AUS
NZ
UK
CA
USA
IND
Healthcare
AdAlta is focusing on an 'East to West' approach for cellular immunotherapy to enhance value creation.
January 22, 2025 11:00 AM AEDT| By Team Kalkine MediaAdAlta's Strategic Move: East to West Cellular Immunotherapy Growth
Ready to Revolutionize Pediatric Neurological Treatments?
January 22, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,● Neurotech International (ASX:NTI) partners with RH Farma Dooel Skopje under a binding development agreement.,● The collaboration focuses on a pharmaceutical-grade broad-spectrum cannabinoid drug for pediatric neurological disorders.,● Th...
Is the Recent Performance of Sonic Healthcare Limited (ASX:SHL) Stock Influenced by Its Financial Health?
January 21, 2025 11:32 PM AEDT| By Team Kalkine MediaIs the Recent Performance of Sonic Healthcare Limited (ASX:SHL) Stock Influenced by Its Financial Health?
SDI Limited Financial Strength Amid Market Fluctuations
January 21, 2025 05:31 PM AEDT| By Team Kalkine MediaSDI Limited Financial Strength Amid Market Fluctuations
Respiri Acquires Orb Health Inc. to Strengthen U.S. Market Position
January 21, 2025 12:04 PM AEDT| By Team Kalkine MediaHighlights,Acquisition of Orb Health:,Respiri has successfully acquired,Orb Health Inc.,for,US$9 million,in shares, marking a significant milestone in its expansion into the,U.S. connected and chronic care health market,.,Additional investment from O...
Lumos Diagnostics (ASX:LDX) Shares Up 31%, Business Prospects Need Improvement
January 21, 2025 11:36 AM AEDT| By Team Kalkine MediaLumos Diagnostics (ASX:LDX) Shares Up 31%, Business Prospects Need Improvement
Insiders Forfeit AU$265k with Emyria Stock Declining to AU$0.03
January 21, 2025 11:35 AM AEDT| By Team Kalkine MediaInsiders Forfeit AU$265k with Emyria Stock Declining to AU$0.03
A year ago, purchasing shares in Ansell (ASX:ANN) would have yielded a 49% return.
January 21, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights:,Ansell Limited (ASX:ANN) shares outperformed the market significantly over the past year.,Total shareholder return outpaces simple share price gains when dividends are included.,Insider buying and analyst forecasts may indicate further po...
ASX Biotech Companies Focused on Early Cancer Detection
January 21, 2025 11:00 AM AEDT| By Team Kalkine MediaPioneering Advances in Cancer Detection by ASX-Listed Biotechs
Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position
January 20, 2025 01:43 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,Ltd. (,ASX:OCC,) receives,a A,$3.18 million R&D tax refund, boosting its cash reserves to A$33 million.,The company is preparing for a US market entry with its innovative medical devices.,A strategic global expansion is underway,...
EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.
January 20, 2025 11:00 AM AEDT| By Team Kalkine MediaEBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.
Optiscan (ASX:OIL) Initiates GI Study in Germany Using Its Initial Imaging Prototype
January 19, 2025 11:00 AM AEDT| By Team Kalkine MediaOptiscan Advances GI Imaging Technology with New Pre-Clinical Study
Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?
January 18, 2025 01:32 PM AEDT| By Team Kalkine MediaIs Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?
Lung Imaging Company Cyclopharm (ASX:CYC) Finds Success in the US Market
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaCyclopharm's Strategic Expansion in the US Healthcare Market
ASX Quarterly Health Summary: EZZ Scores Big, ReNerve's Initial Post-IPO Report
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaEZZ Life Science and Microba Report Strong Q2 FY25 Growth
How Will OPT-302 Transform the Future of Eye Disease Treatment?
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Opthea's lead drug, OPT-302, shows significant promise as a new treatment for challenging eye diseases, such as wet AMD and DME.,If Phase III trials yield positive results, OPT-302 could open a large market opportunity, with peak sales by...
Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies
January 17, 2025 04:30 PM AEDT| By Team Kalkine MediaAustralian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies
Telix Pharmaceuticals (ASX:TLX) Gains After EU Approval for Illuccix in Prostate Cancer Treatment
January 17, 2025 12:37 PM AEDT| By Team Kalkine MediaHighlights,Telix,Pharmaceuticals (,ASX:TLX,) shares jump following European approval.,Illuccix,, the prostate cancer diagnostic agent, gets the green light.,The,stock,has risen by over 140% in the past year.,Telix Pharmaceuticals (ASX:TLX), a Melbour...
ResMed Gains Limelight as Goldman Sachs Sets Bullish Target
January 17, 2025 11:39 AM AEDT| By Team Kalkine MediaHighlights,Strong Performance:,ResMed shares have surged 44% in the past 12 months, showing robust investor confidence in the sleep disorder treatment company.,Analyst Endorsement:,Goldman Sachs has initiated coverage with a,buy,rating and a price ta...
Telix Pharmaceuticals Secures European Authorisation for Prostate Cancer Imaging Agent Illuccix®
January 17, 2025 11:31 AM AEDT| By Team Kalkine MediaHighlights,European Approval for Illuccix®:,Telix Pharmaceuticals received a positive decision on its Marketing Authorization Application (MAA) for Illuccix® across 18 European Economic Area (EEA) member states.,Breakthrough in Prostate Cancer Imagin...
Advertise your brand on Kalkine Media